Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05371353 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 2
    • Start date changed from estimate of May 2022 to May 14, 2022
    v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
Trial Details
NCT Number NCT05371353
Lead Sponsor Shanghai Bovax Biotechnology Co., Ltd.
Conditions
(from sponsor)		 HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart, CIN1, CIN2, CIN3
Related terms Condylomata Acuminata, Papillomavirus Infections, Uterine Cervical Neoplasms, Vaginal Neoplasms
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov